mercoledì, 25 novembre 2020
Medinews
6 Aprile 2018

Denosumab Approved in Europe for Myeloma

April 3, 2018 – The European Commission has approved denosumab for the prevention of skeletal-related events (SREs) in adult patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor. The expanded indication was based on data from the phase III 482 study, in which denosumab demonstrated noninferiority to zoledronic acid at delaying the time to the first SRE in patients with multiple myeloma (0.98; 95% CI, 0.85-1.14; P for … (leggi tutto)

TORNA INDIETRO